ProShare Advisors’s Insight Molecular Diagnostics IMDX Stock Holding History

ProShare Advisors’s Portfolio IMDX Stock Details IMDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-1,041	Closed	-$31K	–	2013
2022 Q1	$31K	Sell	1,041 -266	-20%	-$8.51K	﹤0.01%	2149
2021 Q4	$56K	Buy	+1,307	New	+$75.2K	﹤0.01%	2274
2021 Q3	–	Sell	-919	Closed	-$106K	–	2178
2021 Q2	$106K	Sell	919 -33	-3%	-$3.22K	﹤0.01%	2283
2021 Q1	$99K	Buy	952 +255	+37%	+$24.2K	﹤0.01%	2169
2020 Q4	$33K	Buy	+697	New	+$25.6K	﹤0.01%	2072

Other funds holding IMDX

Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return

PVI

Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return

AIC

AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SSA

Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return

Penbrook Management New York $157M AUM 46.57% 1-Year Est. Return

ProShare Advisors's IMDX Position: Q2 2022 in Review

ProShare Advisors sold out of Insight Molecular Diagnostics (IMDX) in Q2 2022, closing a stake of 1,041 shares — an estimated $31K sold.

ProShare Advisors first reported a position in IMDX in Q4 2020 and held it in 5 quarters. The position peaked at $106K in Q2 2021. 75 funds tracked by Wall St. Rank hold IMDX as of Q2 2022.

ProShare Advisors reported no remaining Insight Molecular Diagnostics position as of Q2 2022 after selling out during the quarter.
ProShare Advisors sold 1,041 Insight Molecular Diagnostics shares in Q2 2022, an estimated $31K.
ProShare Advisors first reported a position in Insight Molecular Diagnostics in Q4 2020 and held it in 5 quarters.
ProShare Advisors's Insight Molecular Diagnostics position peaked at $106K in Q2 2021.
75 funds tracked by Wall St. Rank held Insight Molecular Diagnostics as of Q2 2022.

Based on ProShare Advisors's 13F filing for Q2 2022, filed 1 Aug 2022.